Postnatal diagnosis of single-suture craniosynostosis with cranial ultrasound: a systematic review.

Introduction: The optimal protocol for diagnostic workup of craniosynostosis and the role of specific imaging modalities remain controversial. Skull X-rays and 3-dimensional head CTs are options when physical exam is equivocal but involve ionizing radiation. Ultrasound has emerged as an alternative modality for visualization of cranial sutures, but its use is not widespread.

Early success of the arthroscopic-assisted locked loop suprapectoral biceps tenodesis.

Background: There is wide variability in surgical technique for biceps tenodesis. Prior biomechanical studies have demonstrated superior ultimate and fatigue strength with a Krakow-type locked loop when compared with simple suture and lasso-loop configurations; however, this had not yet been clinically studied. The purpose of this study was to assess the short-term results an arthroscopic-assisted locked loop (ALL) suprapectoral biceps tenodesis technique.

Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine.

The aim of this study was to evaluate the Bio-Quant Direct ELISA assays for amphetamine and methamphetamine in the routine presumptive screening of biological fluids. Standard concentration curves of the target analytes were assayed to assess sensitivity, and known concentrations of common amphetamine-type substances (ephedrine, pseudoephedrine, phentermine), designer analogues (MDA, MDMA, MDEA, MBDB, PMA, 4-MTA, 2CB), and putrefactive amines (phenylethylamine, putrescine, tryptamine, tyramine) were analyzed to determine cross-reactivity. Results of the standard curve studies show the capacity of both Direct ELISA kits to confidently detect down to 3 ng/mL interday (PBS matrix; CVs 6.

Product ion mass spectra of amphetamine-type substances, designer analogues, and ketamine using ultra-performance liquid chromatography/tandem mass spectrometry.

This paper describes the application of ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) technology to separate and identify amphetamine-type substances (amphetamine, methamphetamine), common and novel designer analogues (MDA, MDMA, PMA, 4-MTA, MBDB), and ketamine using Acquity UPLC/Micromass Quattro Micro API mass spectrometer instrumentation (Waters Corporation, USA). From injection of drug reference standards, it was demonstrated that these compounds can be identified by product ion mass spectra in less than 4 min total analysis time, indicating that the technological advancements associated with UPLC/MS/MS allow it to serve as a powerful analytical tool for high-throughput testing. In addition to demonstrating the separation and response of these drug compounds under the stated UPLC/MS/MS conditions, we believe the acquired product ion spectra will be a beneficial reference to laboratories interested in incorporating the use of this technology in the routine analysis of drugs of abuse.

A demonstration of the use of ultra-performance liquid chromatography-mass spectrometry [UPLC/MS] in the determination of amphetamine-type substances and ketamine for forensic and toxicological analysis.

We have recently seen the emergence of ultra-performance liquid chromatography (UPLC) coupled to mass spectrometry as an alternative to traditional high-performance liquid chromatography techniques. The strengths of UPLC technology promote the ability to separate and identify drug compounds with significant gains in resolution and sensitivity and marked reductions in the overall time of analysis. As increased throughput is the desire of the practical toxicology laboratory, the aim of this study was to trial commercially available technology by assessment of the separation of several commonly encountered amphetamine-type substances.

Undecacarbonyl(methylcyclopentadienyl)-tetrahedro-triiridiummolybdenum, undecacarbonyl(tetramethylcyclopentadienyl)-tetrahedro-triiridiummolybdenum and undecacarbonyl(pentamethylcyclopentadienyl)-tetrahedro-triiridiummolybdenum.

The three title compounds tri-mu-carbonyl-1:2kappa2C;1:3kappa2C;2:3kappa2C-octacarbonyl-1kappaC,2kappa2C,3kappa2C,4kappa3C-eta5-methylcyclopentadienyl-tetrahedro-triiridiummolybdenum(3 Ir-Ir)(3 Ir-Mo), tri-mu-carbonyl-1:2kappa2C;1:3kappa2C;2:3kappa2C-octacarbonyl-1kappaC,2kappa2C,3kappa2C,4kappa3C-eta5-tetramethylcyclopentadienyl-tetrahedro-triiridiummolybdenum(3 Ir-Ir)(3 Ir-Mo) and tri-mu-carbonyl-1:2kappa2C;1:3kappa2C;2:3kappa2C-octacarbonyl-1kappaC,2kappa2C,3kappa2C,4kappa3C-eta5-pentamethylcyclopentadienyl-tetrahedro-triiridiummolybdenum(3 Ir-Ir)(3 Ir-Mo), [MoIr(3)(eta5-C(5)H(5-n)Me(n))(mu-CO)(3)(CO)(8)], where n = 1, 4 or 5, have a pseudotetrahedral MoIr(3) core geometry, with a eta5-C(5)H(5-n)Me(n) group ligating the Mo atom, bridging carbonyls spanning the edges of an MoIr(2) face, and eight terminally bound carbonyls.